-2.7%
SMCI vs MRNA
+511.3%
-514.0%
-65.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.5% | -2.2% | +6.8% | +4.6% |
| 7D | +6.8% | +5.5% | +1.3% | +6.6% |
| 30D | +30.6% | +158.7% | -128.2% | +21.2% |
| 3M | -15.6% | +182.1% | -197.7% | -27.0% |
| 6M | +21.3% | +151.8% | -130.6% | +7.6% |
| YTD | +35.3% | +393.6% | -358.3% | +3.4% |
| 1Y | -2.7% | +499.5% | -502.2% | -28.0% |
| All | -2.7% | +511.3% | -514.0% | -28.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling